Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2026-02-06 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated February 6, 2026, announcing the financial results for the quarter and nine months ended December 31, 2025. It includes detailed financial data such as revenue, EBITDA, PAT, segmental business performance, and management commentary. The document references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of financial results. The content is comprehensive and includes actual financial statements and analysis for the interim period (quarter and nine months), not just a brief announcement or a link to a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K), nor is it merely a press release or presentation (IP), nor a report publication announcement (RPA). The length and detail confirm it is a substantive financial report for a period shorter than a full fiscal year. 9M 2026
2026-02-06 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 92% confidence The document is a Board Meeting outcome under SEBI LODR that approves and encloses the company’s Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025, together with the Limited Review Report and full interim financial statements. This is a comprehensive interim/quarterly financial report for a period shorter than a fiscal year, not merely an announcement that a report is available. Therefore, it should be classified as an Interim / Quarterly Report (IR). 9M 2025
2026-02-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges about an upcoming investors/analysts meeting scheduled for February 10, 2026. It references a Q3 FY26 earnings presentation that will be filed later on February 6, 2026, indicating that the actual earnings results are not included in this document. The document is short (2124 characters) and serves as an announcement of a meeting to discuss upcoming financial results, not the results themselves. Therefore, it is not an Earnings Release (ER) or Interim Report (IR), but rather a Regulatory Filing (RNS) as it is a general regulatory announcement informing about investor meetings and upcoming filings.
2026-02-02 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an intimation letter to stock exchanges about upcoming investor/analyst meetings scheduled for February 9, 2026. It references that the Q3 FY26 earnings presentation will be discussed in these meetings and that the financial results will be filed on February 6, 2026. The document itself does not contain any financial data or the earnings presentation but is merely an announcement of the meeting and the upcoming filing. The document length is short (2577 characters) and serves as a notification rather than the report itself. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about investor meetings and upcoming filings, not the earnings release or presentation itself.
2026-02-02 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-01-22 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice dated January 22, 2026, informing the stock exchanges about a scheduled Board Meeting on February 6, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. It references upcoming financial results but does not contain any actual financial data or results itself. The document is an intimation or announcement of a board meeting related to financial results, not the financial report itself. The length is only 1388 characters, which is very short and consistent with an announcement rather than a full report. Therefore, this document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2026-01-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.